Viva Biotech Holdings

OTCPK:VBIZ.F Stock Report

Market Cap: US$477.1m

Viva Biotech Holdings Management

Management criteria checks 4/4

Viva Biotech Holdings' CEO is Chen Cheney Mao, appointed in Jul 2018, has a tenure of 6.83 years. total yearly compensation is CN¥3.08M, comprised of 77.7% salary and 22.3% bonuses, including company stock and options. directly owns 15.9% of the company’s shares, worth $75.87M. The average tenure of the management team and the board of directors is 4.1 years and 6.1 years respectively.

Key information

Chen Cheney Mao

Chief executive officer

CN¥3.1m

Total compensation

CEO salary percentage77.69%
CEO tenure6.8yrs
CEO ownership15.9%
Management average tenure4.1yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chen Cheney Mao's remuneration changed compared to Viva Biotech Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024CN¥3mCN¥2m

CN¥167m

Sep 30 2024n/an/a

CN¥83m

Jun 30 2024n/an/a

-CN¥318k

Mar 31 2024n/an/a

-CN¥58m

Dec 31 2023CN¥2mCN¥1m

-CN¥116m

Sep 30 2023n/an/a

-CN¥276m

Jun 30 2023n/an/a

-CN¥436m

Mar 31 2023n/an/a

-CN¥482m

Dec 31 2022CN¥3mCN¥1m

-CN¥528m

Sep 30 2022n/an/a

-CN¥209m

Jun 30 2022n/an/a

CN¥111m

Mar 31 2022n/an/a

CN¥199m

Dec 31 2021CN¥2mCN¥1m

CN¥288m

Sep 30 2021n/an/a

CN¥258m

Jun 30 2021n/an/a

CN¥228m

Mar 31 2021n/an/a

-CN¥79m

Dec 31 2020CN¥1mCN¥957k

-CN¥387m

Sep 30 2020n/an/a

-CN¥349m

Jun 30 2020n/an/a

-CN¥311m

Mar 31 2020n/an/a

-CN¥23m

Dec 31 2019CN¥1mCN¥954k

CN¥266m

Compensation vs Market: Chen Cheney's total compensation ($USD426.36K) is below average for companies of similar size in the US market ($USD2.68M).

Compensation vs Earnings: Chen Cheney's compensation has been consistent with company performance over the past year.

CEO

Chen Cheney Mao (61 yo)

6.8yrs
Tenure
CN¥3,079,000
Compensation

Dr. Chen Cheney Mao, Ph D has been Chairman of Viva Biotech Holdings since July 03, 2018 and served as Chief Executive Officer of Viva Biotech Holdings since July 03, 2018 until December 1, 2023. He Founde...

Leadership Team

NamePositionTenureCompensationOwnership
Chen Cheney Mao
Chairman & CEO6.8yrsCN¥3.08m15.9%
$ 75.9m
Ying Wu
Executive VP & Executive Director6.8yrsno data0.82%
$ 3.9m
Delin Ren
Executive Director1.4yrsCN¥4.67m0.70%
$ 3.4m
Wei Xiong
Chief Financial Officerless than a yearno datano data
Xueheng Cheng
Chief Technology Officer5.8yrsno datano data
Zhixiong Ye
Chief Scientific Officer6.8yrsno datano data
Han Dai
Chief Innovation Officer & Head of Viva BioInnovatorno datano datano data
Jianhua Cai
Senior Vice President of Via Biotech Shanghaino datano datano data
Jianguo Ma
Senior VP & President of Shanghai Langhua Pharmaceuticalno datano datano data
Xianyong Bu
CBO & EVP of Viva Biotech (Shanghai)no datano datano data
Rongqiang Liu
Senior Vice President of Via Biotech Shanghai2.5yrsno datano data
Derek Ren
CEO of Viva Biotech (Shanghai) Ltd.1.3yrsno datano data
4.1yrs
Average Tenure
60.5yo
Average Age

Experienced Management: VBIZ.F's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chen Cheney Mao
Chairman & CEO6.8yrsCN¥3.08m15.9%
$ 75.9m
Ying Wu
Executive VP & Executive Director15.7yrsno data0.82%
$ 3.9m
Delin Ren
Executive Director6.8yrsCN¥4.67m0.70%
$ 3.4m
Haiguang Wang
Independent Non-Executive Director6.1yrsCN¥228.00kno data
Lei Fu
Independent Non-Executive Director6.1yrsCN¥228.00kno data
Xiangrong Li
Independent Non-Executive Director6.1yrsCN¥228.00kno data
Yuting Wu
Non-Executive Director2.5yrsCN¥228.00kno data
Hui Wang
Non-Executive Director1.3yrsno data4.03%
$ 19.2m
6.1yrs
Average Tenure
60yo
Average Age

Experienced Board: VBIZ.F's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 19:29
End of Day Share Price 2025/04/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Viva Biotech Holdings is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wai Chak YuenBOCI Research Ltd.
Dennis IpDaiwa Securities Co. Ltd.
Xiao Wei LinEverbright Securities Co. Ltd.